Depomed licenses Acuform to Boehringer

Depomed says Boehringer Ingelheim licensed worldwide rights to Depomed's Acuform gastric retentive drug delivery technology to develop and commercialize extended release metformin for type 2 diabetes, among other compounds.

"We are pleased to have closed our third licensing deal for our extended release metformin technology. The upfront and future milestone payments will strengthen our balance sheet, while the potential royalties will add to our revenue build-up as a specialty pharmaceutical company," said Carl Pelzel, president and CEO of Depomed, in a news release.

Under the terms of the agreement, Boehringer Ingelheim is responsible for development and commercialization of the product. Depomed will receive a $12.5 million license fee, $10 million of which is payable upfront, with an additional $2.5 million payable upon delivery of experimental batches of prototype formulations.

- read the Depomed release

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.